The plan is titled “Strengthening Our National System for Medical Device Postmarket Surveillance.”
It includes strategies FDA is taking to implement the system, according to the release. It also includes suggestions on the establishment of unique device identifications for medical devices.
To read the plan and submit comments, click here.
Related Articles on MDMA:
MDMA Issues Statement on GAO Implantable Medical Device Procedures Report
MDMA Continues Push for Repeal of Medical Device Tax
IOM Calls for Overhaul of FDA Device Approval Process; MDMA Disagrees
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
